Kimal has announced that its successful CeltACD femoral artery closure device has reached a new milestone in clinical usage.
Dr Attila Kardos, consultant cardiologist at Milton Keynes Hospital, was responsible for implanting CeltACD in the 1,000th patient to benefit from the product since it was launched.
This comes only a few months after the milestone 500th usage of the device was carried out by German vascular surgeon Dr Arne Schwindt, who praised the model as being a "safe and reliable alternative to established closure devices".
CeltACD is currently only available in Europe and offers a number of practical advantages in femoral arterial closure procedures, offering almost immediate haemostasis, even among anticoagulated patients.
It is simple and easy to use, allowing a medical-grade stainless steel implant to be deployed in just three steps without any need for to change the introducer sheath used during the procedure, while it also allows for immediate re-access if needed, unlike absorbable devices.
The device is limited to investigational use only in the US and is yet to go on sale in this territory.See all the latest jobs in Medical Devices